FID Recht - Recht und Lebenswissenschaften

Wrongful conviction and selection: perceptions of exonerees navigating societal reintegration

2026-09-06T08:21:26+00:00

Credibility, sympathy and culpability in child sexual abuse cases: the role of gender and age

2026-09-04T03:45:40+00:00

Firesetting Intervention Program for Prisoners: a mixed-methods exploratory study of the individual format delivery

2026-09-01T06:42:09+00:00

Trust in the police: understanding ethnic minority and majority differences through the multidimensional Intergroup Trust Model

2026-09-01T07:14:33+00:00

Crime-related photographs do not improve eyewitnesses’ ability to detect the culprit’s presence within the lineup

2026-08-29T11:36:56+00:00

Non-approval in the sunlight: FDA’s CRL disclosures, the limits of confidentiality, and lessons from the EMA

2026-08-26T00:00:00+00:00

Abstract

The US Food and Drug Administration (FDA) issues complete response letters (CRLs) after completing a review when it determines that it cannot approve a drug or biological product application in its current form. Historically, the FDA has treated CRLs as confidential, leaving sponsors largely in control of how non-approval decisions are described publicly. This approach has been criticized for relying on an expansive view of confidentiality, which can obscure safety, efficacy, and quality-related concerns, and for enabling selective or incomplete sponsor communications. In 2025, the FDA shifted course. On July 10, 2025, the FDA posted more than 200 CRLs tied to applications that had subsequently been approved, consolidating information that was often already embedded in the approval action packages. On September 4, 2025, the FDA released 89 previously unpublished CRLs for pending or withdrawn applications, and committed to real-time disclosure of newly issued CRLs going forward. Using a comparative FDA-European Medicines Agency (EMA) lens, we assess what these initiatives changed at launch and how early implementation through May 2026 affects their durability, legal footing, and information value. By May 2026, the FDA’s CRL initiative had evolved into a functioning yet unsettled disclosure infrastructure: openFDA now offers searchable access to CRLs for approved and unapproved applications, while the FDA’s FY 2027 budget request simultaneously seeks clearer statutory authority to disclose certain information in CRLs. We argue that FDA CRLs and EMA assessment outputs are complementary, and we propose lessons that FDA can learn from the EMA to maximize the value of CRL disclosure: codifying timelines and redaction standards, adding neutral decisional summaries where redactions or technical language would otherwise obscure the basis for non-approval, and standardizing the classification and discoverability of prior-cycle CRLs in approval packages. These reforms can protect legitimate confidential commercial information while enabling learning from unsuccessful applications.

A decade of HartBreak: how the use of the Mr. Big Technique has (not) changed since R v Hart (2014)

2026-08-21T05:39:14+00:00

Regulating human reproductive and developmental biotechnologies: a UK reference model

2026-08-21T00:00:00+00:00

Abstract

Rapid scientific change is exposing the limits of the UK’s regulation of human reproductive and developmental biology. Embryo-like structures, in vitro gametogenesis, organoids and heritable genome editing advance understanding of human development and physiology and support new applications in assisted reproduction and clinical care, yet the current regulatory framework is ill-equipped to govern them coherently. A case is made for coordinated, technology-neutral regulatory change. The article proposes the principles of a model UK Human Reproductive and Developmental Biotechnology Act and regulator, the Human Reproductive and Developmental Biotechnology Authority—or HRBA, pronounced ‘harbor’—to provide a permissions route across research and translation. The model Act is a modular, risk-tiered scheme with consistent standards and tailored red lines. It is designed to accommodate boundary cases, to integrate and build upon the existing remit of the Human Fertilisation and Embryology Authority, and coordinate with other established regulators to retain institutional expertise and avoid unnecessary duplication. The proposal is ambitious and would help give effect to UK Government commitments to safely advance the life sciences in this area. But even if piecemeal amendments are ultimately favored, it clarifies the underlying choices and trade-offs and provides a benchmark against which changes can be tested.

Revisiting thin slicing: the effect of exposure length on decision-making processes and deception detection

2026-08-19T06:01:55+00:00

Toward a suffering-informed framework of antisocial youth trajectories: preliminary mixed-method evidence on compassion-flow configurations

2026-08-18T07:23:17+00:00

Beyond fairness: explaining incarcerated people’s willingness to cooperate with correctional officers

2026-08-17T04:24:02+00:00

The biologics manufacturing patent notice challenge: a comparative examination

2026-08-14T00:00:00+00:00

ABSTRACT

In a recent study, we created and analyzed a novel dataset of US biologics manufacturing patents held by nine leading firms that produce originator therapeutic proteins. Here, we expand our data and analysis to encompass not simply US patents but also their family members, with the total set constituting a substantially broader group of patents held internationally. Our wider focus allows us to compare firm strategies in the USA and other jurisdictions. We also contrast the strategies of US-based firms with those headquartered in Europe. Unlike prior comparative studies, which focus primarily on litigated patents, we assess a broader competitive landscape. Our analysis yields several findings. First, all nine firms accumulate many more biologics patents in the USA than in jurisdictions like Europe and Japan. They do so in part by accumulating large numbers of patents with claims of varying scope over a long time period within a given US family. Second, we show distinct patterns of patent accumulation based on firm type. US-based firms with origins in biologics research and development (R&D) that continue to have internally focused R&D efforts dominate patent accumulation not only in the USA but also in Europe and Japan. In contrast, firms that make small molecules in addition to biologics secure fewer patents, regardless of their location. As a detailed illustration of patent practice, we provide a case study of Regeneron’s Eylea. Overall, our findings indicate a substantial notice challenge for biosimilar entry and provide support for reform that increases transparency and information flow regarding biologics patents generally, and manufacturing process patents specifically. Our results also support mechanisms for reducing the anti-competitive impact of large patent families, such as limitations on the number of late-filed patents within a family that can be asserted against biosimilar firms.

Linking childhood adversity to psychopathic traits and empathy in incarcerated women: the role of executive functioning and emotional processing

2026-08-13T06:54:52+00:00

Development and validation of the Sources of Stress and Unease in Incarcerated Individuals Scale (SSUIS): a psychometric instrument for assessing inmate stressors in correctional settings. An exploratory study

2026-08-13T06:24:55+00:00

Interrater reliability and concurrent validity of the sexual violence risk–20 (SVR–20) V2 in South Korean sexual offenders

2026-08-11T05:28:19+00:00

Confirmatory factor analysis of the Prison Adjustment Questionnaire (PAQ) amongst South African adult male incarcerated offenders

2026-08-08T01:30:27+00:00

Predicting disciplinary infractions and recidivism with PICTS spiked profiles in an effort to determine whether sentimentality is a genuine criminal thinking style

2026-08-05T07:33:07+00:00

‘Anything meaningful is just a dream’: perceived disruption of Maslow’s Hierarchy of Needs among female partners and mothers affected by sex offender registration and notification

2026-08-04T01:26:08+00:00

Empathy and social-cognitive functioning in justice-involved adolescents: independent associations with recidivism

2026-07-30T07:29:53+00:00

Frequency of adverse childhood experiences in sex offenders: a systematic review and meta-analysis

2026-07-29T04:10:50+00:00

Adolescent internalizing and externalizing behaviors as predictors of TriPM traits in early adulthood: a longitudinal study

2026-07-28T11:18:34+00:00

The effect of crime type and knowledge about autism spectrum condition (ASC) on the judgement of defendants with ASC

2026-07-28T04:59:37+00:00

Comparing experiences of cyberstalking from victim and perpetrator perspectives

2026-07-28T08:39:39+00:00

Prosecutors’ perceptions of the effectiveness of police interview practices

2026-07-27T02:51:43+00:00

Exploring adolescents’ willingness to report experienced victimization

2026-07-27T06:55:09+00:00

‘Gaze vs. face: emotion recognition and personality traits in community and offending male adolescents’

2026-07-25T10:25:28+00:00

Exploring the relevance of perceived social climate in juvenile forensic settings: a scoping review

2026-07-23T05:21:38+00:00

Exploring the different manifestations of anger in sexual homicide

2026-07-22T03:45:26+00:00

Aided Augmentative and Alternative Communication (AAC) in investigative settings: conveying witnessed events via communication boards

2026-07-22T04:34:57+00:00

Public perceptions of eyewitness interview formats

2026-07-17T01:41:59+00:00

When words paint the picture: accurate eyewitness IDs without visual imagery

2026-07-16T10:54:58+00:00

The impact of child sexual abuse material (CSAM): A systematic review of victim-survivor, caregiver and professional qualitative perspectives

2026-07-15T07:28:03+00:00

Psychological assessment in legal contexts: a survey of Indonesian psychologists

2026-07-15T01:13:57+00:00

The policing zeitgeist of ‘threat’, ‘harm’ and ‘risk’ in England and Wales: a systematic review to untangle their definition and operationalisation

2026-07-14T10:39:10+00:00

The dark path to psychopathy, Machiavellianism as a mediator of the narcissism–psychopathy link among incarcerated men and women: a moderated mediation analysis

2026-07-14T04:04:58+00:00

Cumulative effects of risk factors and protective factors for cybercrime offending

2026-07-14T06:17:33+00:00

Gender differences in antisocial behavior depend on population context: evidence from community and juvenile justice samples in Spain

2026-07-14T02:39:19+00:00

Will remote forensic evaluations make you look bad in court? The influence of attorney questioning on expert credibility

2026-07-13T11:39:04+00:00

The role of attentional interventions and individual differences in the detection of low prevalence fake IDs

2026-07-13T05:41:49+00:00

How does the presence and level of intellectual disability and type of behaviour displayed shape public perceptions of culpability?

2026-07-13T02:55:37+00:00

An integrative model of individual differences and attitudes on policy support: the psychology of hardline penal policy preferences in the United States

2026-07-12T04:55:36+00:00

The effect of time to report and severity on judgments of victims

2026-07-10T09:07:57+00:00

Mock-jurors are insensitive to accuracy differences between showups and lineups

2026-07-08T11:33:18+00:00

Biobanks as fiduciaries of biosamples and data: a legal and ethical analysis in the light of international standards

2026-07-07T00:00:00+00:00

Abstract

This article argues that biobanks are best conceptualized as fiduciaries of biospecimens and associated data. Building on fiduciary legal theory and Anglo-American fiduciary jurisprudence, it explains how long-term discretionary control, informational asymmetry, and donors’ limited ability to monitor downstream uses justify duties of care and loyalty, even though legal recognition and enforceability remain jurisdiction-dependent. The argument is situated within earlier trust-based and fiduciary accounts of biobank governance and is connected to international governance standards, including ISO 20387 (which frames the biobank as a legal entity) and the International Society for Biological and Environmental Repositories Best Practices, treating them as practical specifications of fiduciary stewardship rather than sources of binding law. The fiduciary framework reconceives broad consent as an ongoing governance commitment rather than a one-time authorization, justifies cost recovery as reimbursement for professional stewardship, and subjects intellectual property and benefit-allocation arrangements to loyalty-based constraints. It also situates this fiduciary approach alongside EU General Data Protection Regulation principles of accountability, purpose limitation, and transparency. It argues that public trust is a condition of sustainable biobank governance and that fiduciary governance supports proactive, accountable promotion of research uses of samples and data.

A long-term study of stalking recidivism

2026-07-06T12:11:07+00:00

Evaluating confessions in context: a policy-capturing study

2026-07-01T03:45:45+00:00

Housing stigma: the effects of wrongful conviction and mental illness

2026-06-23T11:57:42+00:00

Laypeople struggle to understand eyewitness evidence indicative of innocence and may perceive face recognition ability as more important than confidence

2026-06-02T06:59:12+00:00

‘I can see your pain, but I don't want to help you’: How observers react to the pain of individuals charged with violent crimes

2026-05-12T05:16:29+00:00

Examining pathways to recidivism risk in detained adolescents according to the Good Lives Model

2026-05-11T07:05:16+00:00

Does self-identity matter? the mediating role of deviant self-identity between informal labeling and adolescent deviance

2026-05-06T05:20:15+00:00

Rapport-based interpersonal techniques: the role of victim engagement

2026-05-05T07:50:46+00:00

Shedding light on deception: exploring an attribution approach

2026-05-05T06:36:30+00:00

A real-world validation of the Risk for Sexual Violence Protocol (RSVP)

2026-04-29T03:29:05+00:00

A European-wide survey of police officers’ beliefs and perceptions on suspect interviews

2026-04-01T02:18:45+00:00

How evidence of confession contamination affects perceptions and judgments in a mock case

2026-03-24T03:32:34+00:00

Factors influencing support for parole in Canada: beliefs about crime and people who commit crime are more important than demographics

2026-03-19T08:15:24+00:00

The relationship between early maladaptive schemas and non-consensual condom removal in an Australian sample

2026-03-12T06:13:21+00:00

Motivational interviewing in criminal justice settings: a systematic literature review

2026-03-10T08:25:27+00:00

Trauma-informed policing: a scoping review

2026-03-10T07:31:44+00:00